Jurkat E6.1 Cells
USD$395.00*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
Overview of Jurkat E6.1 cells
| Description | Jurkat E6.1 cells, a derivative clone of the Jurkat cell line, which originates from the peripheral blood of a 14-year-old boy with acute T-cell leukemia, are a pivotal resource in the field of tumor immunology and leukemia research. These cells exhibit rapid proliferation and a pronounced responsiveness to stimuli, crucial for studying T cell biology, including T cell receptor (TCR) signaling, activation, proliferation, and apoptosis. Characterized by mutations such as the TEL-JAK2 fusion gene, Jurkat E6.1 cells provide insights into the leukemia phenotype and the molecular mechanisms underlying T-cell leukemia. Jurkat E6.1 cells are commonly used to investigate the intracellular signaling pathways that are activated upon TCR engagement, such as the NF-κB pathway, MAPK pathways, and calcium signaling, which are crucial for T cell activation and function. The cell line's responsiveness to phorbol esters and agents targeting the T3 antigen makes it an invaluable tool for exploring the intricacies of T-cell activation, including the induction of Interleukin-2 (IL-2) production. This feature, combined with their abnormal karyotype, underscores the utility of Jurkat E6.1 cells in research focused on the immune synapse architecture and the signaling pathways that govern T-cell proliferation and function. Jurkat E6.1 cells' utility extends to the study of apoptosis, offering a model to investigate the effects of various compounds, including alkaloids extract from sources such as Tribulus terrestris, on cell death pathways. This aspect is particularly relevant for identifying potential therapeutic agents and understanding their mechanisms of action in T-cell leukemia. In summary, Jurkat E6.1 cells, with their unique characteristics and versatility, continue to be a cornerstone in the study of T-cell activation, signaling, and apoptosis. |
|---|---|
| Organism | Human |
| Tissue | Blood |
| Disease | Acute T cell leukemia |
| Metastatic site | T lymphocyte |
| Synonyms | JurkatE6-1, Jurkat E6-1, Jurkat, Clone E6-1, Jurkat Clone E6-1, Jurkat (clone E6-1), JURKAT E-6.1, JURKAT E-61, Jurkat-E6, Jurkat E6, J.E6-1, E6-1 |
Properties
| Age | 14 years |
|---|---|
| Gender | Male |
| Morphology | Round cells |
| Cell type | Lymphoblast |
| Growth properties | Suspension |
Specifications of the Jurkat clone E6 cell line
| Citation | Jurkat E6.1 (Cytion catalog number 300223) |
|---|---|
| Biosafety level | 1 |
| NCBI_TaxID | 9606 |
| CellosaurusAccession | CVCL_0367 |
Genetic profile
| Antigen expression | CD3 |
|---|---|
| Products | Interleukin-2 (interleukin 2, IL-2), interferon gamma |
| Karyotype | Modal number = 46, range = 41 to 47, the karyotype is 46,xY,-2,-18, del(2)(p21p23), del(18)(p11.2) |
Handling Jurkat E6.1 cells
| Culture Medium | RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) |
|---|---|
| Supplements | Supplement the medium with 10% FBS |
| Subculturing | Maintain cultures by periodically adding or replacing the medium. Initiate cultures with a density of 5 x 105 cells/ml and keep the cell concentration within the range of 3 x 105 to 1 x 106 cells/ml for optimal growth. |
| Seeding density | 1 x 105 cells/ml |
| Fluid renewal | Every 2 days |
| Post-Thaw Recovery | Fast |
| Freeze medium | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| Thawing and Culturing Cells |
|
| Incubation Atmosphere | 37°C, 5% CO2, humidified atmosphere. |
| Shipping Conditions | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Storage Conditions | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Quality control
| Sterility | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|
Certificate of Analysis (CoA)
| Lot Number | Certificate Type | Date | Catalog Number |
|---|---|---|---|
| 300223-200923 | Certificate of Analysis | 23. May. 2025 | 300223 |
| 300223-040625 | Certificate of Analysis | 21. Jul. 2025 | 300223 |
-
Related products
Related products
THP-1 CellsOrganism Human Tissue The tissue of origin is peripheral blood Disease Leukemia USD$395.00*